Insilico and Hygtia test new brain-penetrating drug in healthy adults

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Insilico Medicine announced completion of first-in-human dosing in the Phase 1 clinical study of ISM8969, an orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for chronic neuroinflammation and central nervous system disorders including Parkinson’s disease.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE